Iloperidone, asenapine and lurasidone: a primer on their current status
The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Three newer atypical antipsychotic drugs were FDA-approved in 2009 and 2010 in the following order: iloperidone, asenapine and lurasidone. The three drugs are indicated for the treatment of acute schizophrenia. Asenapine is also approved for treatment of manic or mixed episodes associated with bipolar I disorder, for the maintenance treatment of schizophrenia and as an adjunctive therapy with lithium or valproate for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults. AREAS COVERED: This review compares and contrasts the current preclinical, clinical, safety and tolerability profiles of the three newer drugs, as reported in published preclinical and clinical studies, product labels, poster presentations and press releases. EXPERT OPINION: Preclinical studies have reported that the three drugs have variable affinities for a wide range of neurotransmitter receptors, and are active in animal models predictive of antipsychotic activity. Asenapine is the first antipsychotic to be administered sublingually, whereas iloperidone requires titration to minimize orthostatic hypotension. Asenapine and lurasidone are associated with dose-related akathisia, whereas iloperidone is not. The three drugs appear to have relatively benign metabolic profiles. The availability of the three novel antipsychotics should provide additional options for improved treatment of schizophrenia and other psychotic disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892 · cited 1×
“Moreover, large-scale clinical trials (CATIE and CUtLASS) suggested that the efficacies of atypical antipsychotics are not superior to older typical agents in chronic schizophrenia patients [19,20].”
BackgroundClozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156 · cited 1×
“Clozapine, the prototype of atypical antipsychotics was another breakthrough in the treatment of schizophrenia [7-9].”
BackgroundJones, P. B., Barnes, T. R. E., Davies, L., Dunn, G., Lloyd, H., Hayhurst, K. P., Murray, R. M., Markwick, A., & Lewis, S. W. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.10.1079 · Cited by 1,105
Goodman and Gilman's The Pharmacological Basis of Therapeutics.
(1986) · Annals of Internal Medicine · doi:10.7326/0003-4819-104-3-453_1 · Cited by 1,011
Leucht, S., Tardy, M., Komossa, K., Heres, S., Kissling, W., Salanti, G., & Davis, J. M. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60239-6 · Cited by 931 · cited 1×
“However, these agents exhibit differences in terms of their efficacies, safety and adherence [14], and are also associated with undesirable side effects such as weight gain and metabolic deficits [15-18].”
BackgroundThe Burden of Schizophrenia on Caregivers: A Review
Awad, A. G., & Voruganti, L. N. P. (2008) · PharmacoEconomics · doi:10.2165/00019053-200826020-00005 · Cited by 809
Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles
Nasrallah, H. A. (2008) · Molecular Psychiatry · doi:10.1038/sj.mp.4002066 · Cited by 714 · cited 1×
“However, these agents exhibit differences in terms of their efficacies, safety and adherence [14], and are also associated with undesirable side effects such as weight gain and metabolic deficits [15-18].”
BackgroundClozapine: A Novel Antipsychotic Agent
Oates, J. A., Wood, A. J. J., Baldessarini, R. J., & Frankenburg, F. R. (1991) · New England Journal of Medicine · doi:10.1056/nejm199103143241107 · Cited by 687
Binding of antipsychotic drugs to human brain receptors
Richelson, E., & Souder, T. (2000) · Life Sciences · doi:10.1016/s0024-3205(00)00911-5 · Cited by 607 · cited 1×
“Iloperidone has high affinity for adrenergic a1 (Ki < 5 nM) and a2C (Ki = 16 nM) receptors, which suggests a higher risk of dizziness, syncope and orthostatic hypotension [22].”
BackgroundMeltzer, H. Y. (1989) · Psychopharmacology · doi:10.1007/bf00442554 · Cited by 602 · cited 1×
“Clozapine, the prototype of atypical antipsychotics was another breakthrough in the treatment of schizophrenia [7-9].”
Background
Metadata
- Authors
- Tarazi, F. I., & Stahl, S. M.
- Venue
- Expert Opinion on Pharmacotherapy
- Publisher
- Informa UK Limited
- Published
- 2012-07-31
- Volume
- 13
- Issue
- 13
- Pages
- 1911-1922
- ISSN
- 1465-6566 (ISSN-L)
- 1744-7666
- OpenAlex
- W2085168171
- Cited by
- 196
- References
- 63
- FWCI
- 2.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Iloperidone, asenapine and lurasidone: a primer on their current status. https://app.cochat.ai/papers/10.1517/14656566.2012.712114
- The paper
- Tarazi, F. I., & Stahl, S. M. (2012). Iloperidone, asenapine and lurasidone: a primer on their current status. Expert Opinion on Pharmacotherapy. https://doi.org/10.1517/14656566.2012.712114
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.